BREAST CANCER

New study links Medicaid expansion to sustained breast cancer survival gains, revealing uneven benefits by race and urging policy action.

Phase 3 interim data show izalontamab brengitecan boosts survival in pretreated metastatic triple‑negative breast cancer, hinting at new standard.

FDA fast tracks ART6043, an oral Polθ inhibitor for gBRCA HER2-negative metastatic breast cancer, showing early activity and potential to overcome PARP resistance.

FDA reviews oral giredestrant plus everolimus for ESR1-mutated ER+ metastatic breast cancer after CDK4/6 failure, with strong PFS gains and manageable safety.

How ancestry, neighborhood stress and chemo side effects shape TNBC outcomes—and why immunotherapy and tailored care can narrow survival gaps.

During a virtual event, Aditya Bardia, MD, MPH and participants weigh elacestrant and imlunestrant, comparing real-world adverse effects and efficacy.

TNBC care shifts to TROP2 ADCs plus immunotherapy, highlighting early relapse needs, sequencing dilem

FDA prioritizes review of datopotamab deruxtecan for treating metastatic triple-negative breast cancer, showing significant survival benefits over chemotherapy.

New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer.

A large-scale analysis reveals novel predictors of survival and resistance mechanisms in metastatic breast cancer treated with T-DXd, enhancing patient stratification.

NCCN updates guidelines to include sacituzumab govitecan as a first-line treatment for metastatic triple-negative breast cancer, enhancing patient options.

New clinical data reveals Bria-IMT's potential to significantly extend survival in patients with heavily pretreated metastatic breast cancer, offering hope for better outcomes.

A virtual collaborative care model enhances mental health support in oncology, improving patient outcomes and addressing care disparities in underserved populations.

A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in patients with untreated metastatic triple-negative breast cancer.

Practice-changing 2025 breast cancer trial updates spotlight giredestrant, tucatinib maintenance, and ribociclib in key subtypes, boosting disease control with manageable safety.

The FDA reviews gedatolisib, a promising treatment for advanced breast cancer, aiming to enhance patient outcomes with innovative combination therapies.

EMA validates T-DXd and pertuzumab for first-line HER2-positive metastatic breast cancer, potentially transforming treatment standards in the EU.

Experts discuss a virtual collaborative care model that integrates mental health support into oncology, enhancing patient care and improving treatment outcomes.

Researchers explore the impact of virtual collaborative care on mental health and quality of life for breast cancer patients, revealing significant improvements.

Atossa Therapeutics advances Z-endoxifen for metastatic breast cancer, showing promise in clinical trials and receiving FDA approval to proceed with studies.

Breakthroughs in breast cancer treatment in 2025 highlight FDA approvals and innovative therapies, enhancing outcomes for HR+, HER2–, and TNBC patients.

FDA designates T-DXd as breakthrough therapy for high-risk HER2-positive early breast cancer, promising improved survival rates over current treatments.

Liquid biopsy enhances risk assessment for patients with neoadjuvant therapy-resistant tumors, guiding treatment decisions and improving survival outcomes.

Sacituzumab govitecan shows a favorable safety profile in treating untreated triple-negative breast cancer, with manageable adverse effects compared to chemotherapy.